Highly Sensitive Antibody-Free μLC–MS/MS Quantification of Rhtrail in Serum

References

• Hopfgartner G , LesurA, VaresioE. Analysis of biopharmaceutical proteins in biological matrices by LC–MS/MS II. LC–MS/MS analysis. TrAC Trends Anal. Chem. 48, 52–61 (2013).
   Web of Science ®Google Scholar
• Van den Broek I , NiessenWMA, van DongenWD. Bioanalytical LC–MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 929, 161–179 (2013).
   PubMed Web of Science ®Google Scholar
• Bults P , van de MerbelNC, BischoffR. Quantification of biopharmaceuticals and biomarkers in complex biological matrices: a comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays. Expert Rev. Proteomics12 (4), 355–374 (2015).
   PubMed Web of Science ®Google Scholar
• Switzar L , GieraM, NiessenWMA. Protein digestion: an overview of the available techniques and recent developments. J. Proteome Res. 12 (3), 1067–1077 (2013).
   PubMed Web of Science ®Google Scholar
• Bischoff R , BronsemaKJ, van de MerbelNC. Analysis of biopharmaceutical proteins in biological matrices by LC–MS/MS I. Sample preparation. TrAC Trends Anal. Chem. 48, 41–51 (2013).
   Web of Science ®Google Scholar
• McAvoy T , LassmanME, SpellmanDSet al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 60 (4), 683–689 (2014).
   PubMed Web of Science ®Google Scholar
• Kuhn E , WhiteakerJR, ManiDRet al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteomics11 (6), M111.013854 (2012).
   PubMed Web of Science ®Google Scholar
• Whiteaker JR , ZhaoL, AbbatielloSEet al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics10 (4), M110.005645 (2011).
   PubMed Web of Science ®Google Scholar
• Becker JO , HoofnagleAN. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC–MS/MS. Bioanalysis4 (3), 281–290 (2012).
   PubMed Web of Science ®Google Scholar
• Palandra J , FinelliA, ZhuM, MasferrerJ, NeubertH. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC–MS/MS. Anal. Chem. 85 (11), 5522–5529 (2013).
   PubMed Web of Science ®Google Scholar
• Bronsema KJ , BischoffR, van de MerbelNC. High-sensitivity LC–MS/MS quantification of peptides and proteins in complex biological samples: the impact of enzymatic digestion and internal standard selection on method performance. Anal. Chem. 85 (20), 9528–9535 (2013).
   PubMed Web of Science ®Google Scholar
• Wilffert D , ReisCR, HermansJet al. Antibody-free LC–MS/MS quantification of rhTRAIL in human and mouse serum. Anal. Chem. 85 (22), 10754–10760 (2013).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A , HollandP, EckhardtSG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26 (21), 3621–3630 (2008).
   PubMed Web of Science ®Google Scholar
• Reis CR , van der SlootAM, NatoniAet al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 1 (10), e83 (2010).
   PubMedGoogle Scholar
• Van der Sloot AM , TurV, SzegezdiEet al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl Acad. Sci. USA103 (23), 8634–9 (2006).
   PubMed Web of Science ®Google Scholar
• Fulda S . Safety and tolerability of TRAIL receptor agonists in cancer treatment. Eur. J. Clin. Pharmacol. 71 (5), 525–527 (2015).
   PubMed Web of Science ®Google Scholar
• Herbst RS , EckhardtSG, KurzrockRet al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 28 (17), 2839–2846 (2010).
   PubMed Web of Science ®Google Scholar
• Soria J-C , SmitE, KhayatDet al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 28 (9), 1527–1533 (2010).
   PubMed Web of Science ®Google Scholar
• Wainberg ZA , MessersmithWA, PeddiPFet al. A Phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin. Colorectal Cancer12 (4), 248–254 (2013).
   PubMed Web of Science ®Google Scholar
• Soria J-C , MárkZ, ZatloukalPet al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J. Clin. Oncol. 29 (33), 4442–4451 (2011).
   PubMed Web of Science ®Google Scholar
• O’Leary L , van der SlootAM, ReisCRet al. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene35 (10), 1261–1270 (2016).
   PubMed Web of Science ®Google Scholar
• Yu R , AlbarenqueSM, CoolRH, QuaxWJ, MohrA, ZwackaRM. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer Biol. Ther. 15 (12), 1658–1666 (2014).
   PubMed Web of Science ®Google Scholar
• Szegezdi E , ReisCR, van der SlootAMet al. Targeting AML through DR4 with a novel variant of rhTRAIL. J. Cell. Mol. Med. 15 (10), 2216–2231 (2011).
   PubMed Web of Science ®Google Scholar
• Duiker EW , de VriesEGE, MahalingamDet al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin. Cancer Res. 15 (6), 2048–2057 (2009).
   PubMed Web of Science ®Google Scholar
• Yu R , DeediganL, AlbarenqueSM, Mohra, ZwackaRM. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis. 4, e503 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao Y , LiuG, AngelesAet al. Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum. J. Chromatogr. B988, 81–87 (2015).
   PubMed Web of Science ®Google Scholar
• Reis CR , van der SlootAM, SzegezdiEet al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry48 (10), 2180–2191 (2009).
   PubMed Web of Science ®Google Scholar
• Yan JX , WaitR, BerkelmanTet al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis21 (17), 3666–3672 (2000).
   PubMed Web of Science ®Google Scholar
• Franciosi L , GovorukhinaN, Ten HackenN, PostmaD, BischoffR. Proteomics of epithelial lining fluid obtained by bronchoscopic microprobe sampling. Methods Mol. Biol. 790, 17–28 (2011).
   PubMedGoogle Scholar
• Wilffert D , BischoffR, van de MerbelNC. Antibody-free workflows for protein quantification by LC–MS/MS. Bioanalysis7 (6), 763–779 (2015).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research, Center for Veterinary Medicine, Guidance for Industry: Bioanalytical Method Validation; Center for Drug Evaluation and Research : Rockville, MD, USA, May 2001. www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use . Guideline on bioanalytical method validation; European Medicines Agency: London, July 2011. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
   Google Scholar